Vice President, Immunology Research - Genentech Research & Early Development

Immunology is one of Genentech/Roche’s five core therapeutic areas of focus, alongside Oncology, Cardiovascular Renal & Metabolism (CVRM), Ophthalmology and Neurology. Breakthroughs in our understanding of human disease, propelled by the development of pathobiology maps, foundational disease models and the integration of artificial intelligence combined with the rapid evolution of computationally assisted drug discovery and therapeutic modalities have unlocked unprecedented opportunities to deliver life-changing medicines for patients.

As we enter a new era of target identification and drug development, the potential to discover and develop transformative therapies has never been greater.

The VP of Immunology Research will oversee an organization of ~70 researchers and will be responsible for the following critical accountabilities:

Shaping and executing our Immunology research strategy to maximize impact

Cultivate an innovative, dynamic and intellectually rigorous environment that inspires groundbreaking discoveries

Seamless collaboration with Drug Discovery to leverage existing and explore novel drug modalities to target key pathogenic pathways underlying human disease

Driving cross-disciplinary research at the interface of immunology and inflammation across multiple therapeutic areas, including:

Neuroscience: focus on neuroimmune strategies to address neurologic diseases

Oncology: enhance understanding to leverage innate immune, adaptive immune and stromal mechanisms for treating hematologic and solid malignancies

Cardiovascular, Renal & Metabolism (CVRM): discover and develop novel therapies targeting the innate and adaptive immune system across a broad range of diseases in this space, including obesity, atherosclerotic cardiovascular disease, heart failure, and kidney disease

Ophthalmology: focus on immunomodulatory approaches for the treatment of eye diseases

Infectious Diseases: investigate the role of the microbiome and host-pathogen interactions in autoimmune and inflammatory diseases; advancing discovery and development of innovative antibacterial and antiviral therapeutics to support Roche’s goals in global health security

Partnering with Corporate Business Development to identify strategic external partnerships around the globe that support our strategy and strengthen the portfolio to create long‑term value for the enterprise

Collaborating with the Translational Medicine organization to deepen insights into human disease heterogeneity, enabling the discovery and development of biomarkers to guide precision medicines and identification of novel targets/pathways through ‘reverse translation’ from the clinic

Partnering with the Center of Excellence in Computational Sciences to incorporate advanced computational approaches and artificial intelligence for novel target discovery/validation and drug discovery and development

Advancing functional genomics efforts in collaboration with our Translational Genomics and Proteomics Center through interrogation of normal and human disease tissues and conducting large scale genomic and small molecule screens to identify novel therapeutic targets and leads, respectively

Working with Early Clinical Development to translate novel biological insights into therapeutic strategies aimed at specific diseases and patient segments

Represent Genentech/Roche externally at scientific conferences and meetings

Manage budgets, resources, and timelines effectively to ensure the successful execution of research programs

Ensure all research activities comply with relevant regulatory requirements and ethical standards

This individual will ensure seamless cross‑functional collaboration while advancing innovative science that transforms the lives of patients

The VP of Immunology Research will report to the Senior Vice President, Research-Biology in gRED Research, an independent R&D division in the Roche group.

The leader will be a:

Member of Research Review Committee Member of the gRED Research Leadership Team Ad‑hoc member of the Early Stage Portfolio Team Ad‑hoc member of teams that are formed to evaluate external innovation and business…